Figure 3.

Reduced calpastatin, increased Transient Receptor Potential channel C6 (TRPC6) expression, and enhanced calcineurin activation in patients with FSGS. (A) Representative pictures of costaining of the endogenous calpain inhibitor calpastatin and nephrin in healthy controls and patients with FSGS. (B) Calpastatin expression in podocytes was determined by quantifying the costaining of calpastatin and nephrin. (C) Cortical calcineurin activity, as a downstream calpain target, was determined as well as (D) cortical TRPC6 mRNA and (E) glomerular TRPC6 protein expression as quantified by immunofluorescence costained with synaptopodin. FSGS, n=3; control, n=5. *P<0.05 compared with healthy controls.